Peer Reviewed
Feature Article Genetics

Familial hypercholesterolaemia – Part 2: Treatment options and screening approaches

John R Burnett, Gerald Watts
Abstract
Undetected and undertreated familial hypercholesterolaemia (FH) is a lethal medical condition. Effective treatments are available for patients with FH; most patients will require a combination of dietary modification and pharmacotherapy to achieve target LDL-cholesterol levels.
Key Points
  • The aim of lipid-regulating therapy is to achieve a target plasma LDL-cholesterol level of <2.6 mmol/L, as well as correction of any coexistent hypertriglyceridaemia and low HDL-cholesterol concentration.
  • Although diet is the cornerstone of treatment of hypercholesterolaemia, it almost never suffices in achieving target LDL-cholesterol levels when used alone in patients with heterozygous FH.
  • The three current drug treatment options for reducing LDL-cholesterol levels are bile acid binding resins, statins and ezetimibe.
  • Other agents that could be added to statins to control dyslipidaemia, especially in patients with coexistent hypertriglyceridaemia and low HDL-cholesterol, include fibrates, nicotinic acid and fish oils.
  • The present marked shortfall in the detection of FH highlights the need to develop a highly cost-effective screening and follow up program.
Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?